Extracellular vesicles-based biomarkers represent a promising liquid biopsy in endometrial cancer
Herrero, Cristina (Instituto de Investigación Sanitaria de Santiago (IDIS))
De La Fuente, Adolfo (Nasasbiotech. S.L.)
Casas-Arozamena, Carlos (Instituto de Investigación Sanitaria de Santiago (IDIS))
Sebastian, Víctor (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina)
Prieto, Martín (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina)
Arruebo, Manuel (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina)
Abalo, Alicia (Instituto de Investigación Sanitaria de Santiago (IDIS))
Colás Ortega, Eva (Hospital Universitari Vall d'Hebron)
Moreno-Bueno, Gema (Fundacion MD Anderson Internacional)
Gil-Moreno, Antonio 1965- (Hospital Universitari Vall d'Hebron)
Vilar, Ana (Instituto de Investigación Sanitaria de Santiago (IDIS))
Cueva, Juan (Centro de Investigación Biomédica en Red de Cáncer)
Abal Posada, Miguel (Centro de Investigación Biomédica en Red de Cáncer)
Muinelo-Romay, Laura (Centro de Investigación Biomédica en Red de Cáncer)
Universitat Autònoma de Barcelona

Data:	2019
Resum:	Tumor-derived extracellular vesicles (EVs) are secreted in large amounts into biological fluids of cancer patients. The analysis of EVs cargoes has been associated with patient's outcome and response to therapy. However, current technologies for EVs isolation are tedious and low cost-efficient for routine clinical implementation. To explore the clinical value of circulating EVs analysis we attempted a proof-of-concept in endometrial cancer (EC) with ExoGAG, an easy to use and highly efficient new technology to enrich EVs. Technical performance was first evaluated using EVs secreted by Hec1A cells. Then, the clinical value of this strategy was questioned by analyzing the levels of two well-known tissue biomarkers in EC, L1 cell adhesion molecule (L1CAM) and Annexin A2 (ANXA2), in EVs purified from plasma in a cohort of 41 EC patients and 20 healthy controls. The results demonstrated the specific content of ANXA2 in the purified EVs fraction, with an accurate sensitivity and specificity for EC diagnosis. Importantly, high ANXA2 levels in circulating EVs were associated with high risk of recurrence and non-endometrioid histology suggesting a potential value as a prognostic biomarker in EC. These results also confirmed ExoGAG technology as a robust technique for the clinical implementation of circulating EVs analyses.
Ajuts:	Instituto de Salud Carlos III PI17/01919 Instituto de Salud Carlos III IFI17/00047
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	EVs ; ExoGAG ; Endometrial cancer ; ANXA2
Publicat a:	Cancers, Vol. 11 Núm. 12 (december 2019) , p. 2000, ISSN 2072-6694

DOI: 10.3390/cancers11122000
PMID: 31842290

14 p, 3.0 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats